A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463
This study is recruiting at 6 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity
- Overweight
- Chronic Weight Management
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Ascletis Pharma (China) Co., Limited
- Last updated on ClinicalTrials.gov
- September 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- AURORA-1 Clinical Site · Phoenix, AZ
Florida · 2
- AURORA-1 Clinical Site · Melbourne, FL
- AURORA-1 Clinical Site · The Villages, FL
Indiana · 1
- AURORA-1 Clinical Site · Evansville, IN
Texas · 2
- AURORA-1 Clinical Site · Austin, TX
- AURORA-1 Clinical Site · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.